Jacobs Levy Equity Management
VERA icon

Jacobs Levy Equity Management’s Vera Therapeutics VERA Stock Holding History

Jacobs Levy Equity Management’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,196
Closed -$871K – 1044
2024
Q1 		$871K Sell
20,196
-275
-1% -$9.8K ﹤0.01% 740
2023
Q4 		$315K Buy
+20,471
New +$260K ﹤0.01% 883

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Jacobs Levy Equity Management's VERA Position: Q2 2024 in Review

Jacobs Levy Equity Management sold out of Vera Therapeutics (VERA) in Q2 2024, closing a stake of 20,196 shares — an estimated $871K sold.

Jacobs Levy Equity Management first reported a position in VERA in Q4 2023 and held it in 2 quarters. The position peaked at $871K in Q1 2024. 171 funds tracked by Wall St. Rank hold VERA as of Q2 2024.

  • Jacobs Levy Equity Management reported no remaining Vera Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 20,196 Vera Therapeutics shares in Q2 2024, an estimated $871K.
  • Jacobs Levy Equity Management first reported a position in Vera Therapeutics in Q4 2023 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Vera Therapeutics position peaked at $871K in Q1 2024.
  • 171 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2024, filed 14 Aug 2024.